A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma

被引：30
作者：
Berg, WJ
Schwartz, LH
Amsterdam, A
Mazumdar, M
Vlamis, V
Law, TM
Nanus, DM
Motzer, RJ
机构：
[1] Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol, Genitourinary Oncol Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Res Lab, New York, NY 10021 USA
[5] Cornell Univ, Coll Med, Dept Med, New York, NY USA
来源：
INVESTIGATIONAL NEW DRUGS | 1997年 / 15卷 / 04期
关键词：
advanced renal cell carcinoma; retinoic acid;
D O I：
10.1023/A:1005902022076
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The aim of this study was to determine the antitumor activity of 13-cis-retinoic acid as a single agent in patients with advanced renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bi-dimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no evidence of brain metastases, and treatment with no more than one chemotherapy regimen. Patients were treated with one mg/kg/day of 13-cis-retinoic acid orally. Twenty-six patients were enrolled in this study and 25 were evaluable for response and toxicity. Of the twenty-five evaluable patients, no major responses were achieved. Toxicity was mild, with no patient requiring a dose reduction. At the dose administered in this trial, 13-cis-retinoic acid is inactive as a single agent in renal cell carcinoma.
引用
收藏
页码：353 / 355
页数：3
相关论文
共 11 条
  • [1] Hoffman AD, 1996, CLIN CANCER RES, V2, P1077
  • [2] A PHASE-II TRIAL OF INTERLEUKIN-2 AND INTERFERON-ALFA-2A IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA
    ILSON, DH
    MOTZER, RJ
    KRADIN, RL
    VOGELZANG, NJ
    BAJORIN, DF
    SCHER, HI
    NANUS, D
    OMOORE, P
    MARATHIAS, K
    BOSL, GJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) : 1124 - 1130
  • [3] LAW TM, 1995, CANCER-AM CANCER SOC, V76, P824, DOI 10.1002/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO
  • [4] 2-N
  • [5] LAW TM, 1994, P AN M AM SOC CLIN, V13, P243
  • [6] MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO
  • [7] 2-6
  • [8] INTERFERON ALFA-2A IN ADVANCED RENAL-CELL CARCINOMA - TREATMENT RESULTS AND SURVIVAL IN 159 PATIENTS WITH LONG-TERM FOLLOW-UP
    MINASIAN, LM
    MOTZER, RJ
    GLUCK, L
    MAZUMDAR, M
    VLAMIS, V
    KROWN, SE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) : 1368 - 1375
  • [9] Renal-cell carcinoma
    Motzer, RJ
    Bander, NH
    Nanus, DM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (12) : 865 - 875
  • [10] INTERFERON ALFA-2A AND 13-CIS-RETINOIC ACID IN RENAL-CELL CARCINOMA - ANTITUMOR-ACTIVITY IN A PHASE-II TRIAL AND INTERACTIONS IN-VITRO
    MOTZER, RJ
    SCHWARTZ, L
    LAW, TM
    MURPHY, BA
    HOFFMAN, AD
    ALBINO, AP
    VLAMIS, V
    NANUS, DM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) : 1950 - 1957
12